The in vitro and in vivo activities of catheters coated with minocycline and rifampin and with chlorhexidine gluconate and silver sulfadiazine were evaluated. When incubated in serum at 37°C, the half-life of the inhibitory activity of catheters coated with minocycline and rifampin was 25 days compared with 3 days for catheters coated with chlorhexidine gluconate and silver sulfadiazine. In a rabbit model, catheters coated with minocyclineand rifampin were significantlymore efficacious than catheters coated with chlorhexidine and silver sulfadiazine in preventing colonization and infection with Staphylococcus aureus (P < .05). Catheters coated with minocycline and rifampin demonstrated broad-spectrum in vitro inhibitory activity against gram-positive bacteria, gramnegative bacteria, and Candida albicans that was significantly superior to the inhibitory activity of catheters coated with chlorhexidine gluconate and silver sulfadiazine (P < .01). Minocycline and rifampin were also highly efficacious in preventing colonization and infection in vivo.
The Broad-Spectrum Activity and Efficacy of Catheters Coated with Minocycline and Rifampin
The in vitro and in vivo activities of catheters coated with minocycline and rifampin and with chlorhexidine gluconate and silver sulfadiazine were evaluated. When incubated in serum at 37°C, the half-life of the inhibitory activity of catheters coated with minocycline and rifampin was 25 days compared with 3 days for catheters coated with chlorhexidine gluconate and silver sulfadiazine. In a rabbit model, catheters coated with minocyclineand rifampin were significantlymore efficacious than catheters coated with chlorhexidine and silver sulfadiazine in preventing colonization and infection with Staphylococcus aureus (P < .05). Catheters coated with minocycline and rifampin demonstrated broad-spectrum in vitro inhibitory activity against gram-positive bacteria, gramnegative bacteria, and Candida albicans that was significantly superior to the inhibitory activity of catheters coated with chlorhexidine gluconate and silver sulfadiazine (P < .01). Minocycline and rifampin were also highly efficacious in preventing colonization and infection in vivo.
Indwelling vascular catheters are a leading cause of primary nosocomial sepsis [1, 2] , and urinary catheters are a leading cause of nosocomial urinary tract infection [3] [4] [5] . Despite their association with infectious complications, these devices are essential for the appropriate management of hospitalized and chronically ill patients.
Colonization of bacteria and fungi is a prelude to catheter infection [6] and is more common than initially thought. Recent data using scanning and transmission electron microscopy have suggested that most indwelling catheters are colonized with bacteria and fungi [7) . Organisms adhere to catheter surfaces and embed in a biofilm layer that consists of host factors such as fibrin, fibronectin, and a microbial exopolysaccharide material [8) . Microorganisms embedded in the biofilm layer are resistant to glycopeptide antibiotics and normal host defenses such as antibodies and phagocytic polymorphonuclear cells [9] [10] [11] [12] .
To limit catheter infections, several interventions have been studied. These include the use of maximal sterile barriers, topical antibiotics or antimicrobial flush solutions, tunneled catheters, subcutaneous ports, and subcutaneous silver cuffs [13] [14] [15] [16] [17] . Most of these interventions have resulted in a significant reduction of catheter infections; however, catheter-related infections continue to occur, often with more resistant organisms, resulting in serious morbidity and mortality [18] .
The antimicrobial coating of catheters has resulted in a significant reduction in the colonization of these devices in vitro and in vivo [19, 20) . A common method of coating catheters involves the use of a cationic surfactant called tridodecylmethyl ammonium chloride (TDMAC) that binds to the catheter surfaces at one end and to anionic antimicrobials at the other. In a prospective randomized clinical trial, Kamal et a!. [21] showed that when cefazolin was bonded to TDMAC-coated catheters the devices were significantly less prone to colonization than were uncoated control catheters. Maki et a!. [22] found that when catheters were coated with chlorhexidine gluconate and silver sulfadiazine (CH-SS), the incidence of catheter-related sepsis was reduced >4-fold.
The issue remaining is which antimicrobial agents should be used to coat the catheter. As a result of the emergence of resistant gram-positive and gram-negative bacteria, ,B-Iactam and glycopeptide antibiotics, which are considered the firstline drugs for treating established infections, should not be used prophylactically. In an in vitro model, minocycline combined with rifampin was more efficacious than other antibiotic combinations, such as vancomycin and rifampin, in preventing colonization of Staphylococcus epidermidis to silicone catheter surfaces [23] . In addition, the minocycline-rifampin combination has broad antistaphylococcal, anti-gram-negative bacillary, and anticandidal activity [24] . This study assessed the in vitro and in vivo efficacy of catheters coated with minocycline and rifampin. In vitro antimicrobial half-life. The half-life of antimicrobial activity of coated catheters was determined by immersing several catheter segments in human serum and incubating the serum at 37°C. Segments were removed for testing at 3, 7, 10, 15, and 30 days. The antimicrobial activity against S. epidermidis at the different intervals was determined by the modified Kirby-Bauer technique (described earlier) and compared with the baseline zones of inhibitions determined on day I before immersion in sera.
Materials and Methods
Levels of antibiotics on catheters. Individual l-cm segments of catheters coated with minocycline-rifampin were extracted in 5 mL of methylene chloride. The segments were sonicated in methylene chloride for 15 min, left to sit for 45 min at room temperature, and vortexed for 5 s. After catheter segments were removed, the extracted solution was air-dried, and the retained antibiotics were suspended in 1 mL of the buffer used for high-performance liquid chromatography (HPLC) as described by Darouiche and Hamill [25] . Aliquots (10 mL) of the extracted antibiotic suspension were injected into the HPLC system (fLBondopackC I 8 bond column [60 A, 4 fLm, 3.9 X 150 mm], model 510 solvent delivery pump, model 700 WISP satellite sample processor, 486 UV absorbance detector, and Maxima 820 operating station; Waters Chromatography Division, Millipore, Milford, MA).
Both minocycline and rifampin were detected under the same I I separation conditions [25] . The mobile phase consisted of KH zP04 (60%) and acetonitrile (40%) with the final pH adjusted to~3.25 using 85% O-phosphoric acid. The HPLC system was run under an isocratic reversed-phase condition with a flow rate of I mLi min. Detection was done at a wavelength of 339 nm. Minocycline was eluted at 1.5 min, and rifampin was detected at 13 min. In pilot trials, known amounts of antibiotics were added to l-cm segments of uncoated catheters and extracted as outlined above. More than 90% of both antibiotics were recovered. After construction of standard curves, antibiotic controls were measured with a consistent accuracy of >85%. Rabbit model of S. aureus infection. We used an established rabbit model (3-to 4-month-old New Zealand White rabbits; 3-4 kg) as described by Sherertz et al. [20] . S. aureus strain PI (ATCC 25923) was obtained from the laboratory of R. 1. Sherertz (Wake Forest University, Bowman-Gray School of Medicine, Winston-Salem, NC). The S. aureus strain was grown overnight in TSB, washed twice in PBS, pH 7.3, and diluted serially in PBS to achieve an inoculum of 10 6 cfu/ml., By use of a tuberculin syringe with a blunt-tipped needle, O.I-mL aliquots of bacterial suspension were delivered subcutaneously next to the lateral catheter segment.
Animals were anesthetized with a l-mL combination of ketamine (80 mg/mL) and xylazine (20 mg/mL). The back of each animal was shaved, depilated with Nair (Carter Wallace, New York), and prepared with povidone iodine (Clinidine; Clinipad, Guilford, CT). We made a pair of incisions (0.5-1 em apart and 4 em from the spine) for each catheter segment. We studied 7 French (13 gauge) triple lumen polyurethane vascular catheters, including some Bio-guard catheters coated with TDMAC only (negative controls), Arrow Gard catheters coated with CH-SS (positive controls), and some coated with minocycline-rifampin. A Jimshidi bone marrow needle (Pharmaseal; Baxter Healthcare, Valencia, CAl was used to create two 3-cm tunnels through two incisions. A 6-cm catheter segment was inserted into both tunnels so that both ends of the catheter were in the subcutaneous space and the middle of the catheter rested on the skin. Four pairs of catheter segments were inserted into each rabbit. The catheter segment closest to the spine (medial) was secured with a silk suture; only the catheter segment without the suture was inoculated. A O.I-mL aliquot of the bacterial suspension of S. aureus PI (10 6 cfu/mL) was inoculated at the insertion site of the lateral segment.
Animals were sacrificed 7 days later. Each catheter segment was removed and observed for gross purulence; the intercutaneous segments were placed in sterile containers and transferred to the laboratory. Each segment was initially cultured semiquantitatively using the roll-plate technique [26] . Each segment was subsequently placed in 5 mL of TSB and cultured quantitatively by the sonication technique [27, 28] .
Data analysis. The significance of differences in the frequencies of categorical variables was determined using the X 2 or Fisher's exact tests. Continuous variables with normal distribution were compared by Student's t test; continuous variables that were not normally distributed were compared by the Mann-Whitney test. P .05 was considered to be statistically significant.
Results
In vitro antimicrobial activity ofcoated catheters. Catheter segments coated with minocycline-rifampin demonstrated a broad-spectrum of activity against bacteria and C. albicans wider halo of presumed partial growth inhibition (figure I). Diameters shown are for the inner zones. Although smaller than the zones of inhibition of minocycline-rifampin-scoated catheters against gram-positive bacteria, the activity against C.
albicans was significantly better (P < .0 I) than that of catheters coated with CH-SS (table I).
Zone of inhibition (mm)
Stability and half-life ofthe antimicrobial activity of coated catheters. Catheters coated with minocycline-rifampin or CH-SS did not show any significant difference in in vitro activity against S. epidermidis or S. aureus before or after gas sterilization with ethylene oxide. In serum at 37°C, the half-life of the antimicrobial activity against S. epidermidis of catheters coated with CH-SS was 3 days versus 25 days for catheters coated with minocycline-rifampin, The zones of inhibition of minocycline-rifampin-scoated catheters at baseline (day I) was 3.2 times greater than those treated with CH-SS. This ratio increased to 4.9 at day 15 and 7.0 at day 30 (figure 2). Figure  3 shows shelf-life data for catheters coated with minocyclinerifampin while stored at 25°C. The zones of inhibition after 12 months were 90% of those at baseline.
The HPLC-determined concentration of minocycline and rifampin on catheters was 290 and 93 jLg/cm, respectively; thus, the concentration of minocycline was> 3-fold higher than that of rifampin.
In vivo activity ofcoated catheters. Seven days after insertion and inoculation, purulence was noted at the insertion site of all control catheters coated with TDMAC only. Semiquantitative cultures of control segments had > 10 3 cfu per 2-cm segment from all 32 catheters ( 
Discussion
Medical devices with antimicrobial activity decrease the risk of colonization and ultimately of infection [19] [20] [21] [22] . Chlorhexidine gluconate is often favored as an antiseptic with broadspectrum activity. Sherertz et al. [20] demonstrated the efficacy of coating catheters with chlorhexidine in vitro and in vivo. In a prospective, randomized clinical trial, Maki et al. [22] reported that catheters coated with TDMAC and CH-SS decreased the risk of catheter-related septicemia by >4-fold. Kamal et al. [21] used TDMAC as a binding surfactant and coated vascular catheters with cefazolin. They reported a significant --Minocycline/Rifampin reduction in catheter colonization. Unlike antibiotics such as cephalosporins or glycopeptides, chlorhexidine gluconate and silver sulfadiazine are broad-spectrum antiseptic agents that are not used therapeutically in the treatment of systemic infections. Almost any antimicrobial agent can be bonded onto the surface of polyurethane catheters. However, in planning an effective preventive strategy, several criteria should be fulfilled before attempting to use these catheters clinically. S. epidermidis (most strains of which are methicillin-resistant) is the most common cause of vascular catheter-related infections [6] . Other common etiologic agents are S. aureus, C. albicans, and some nosocomial strains of resistant gram-negative bacilli (e.g.,
A. baumanii and S. maltophilia) [27] [28] [29] [30] [31] . Therefore, it is preferable that the antimicrobial agents used to coat vascular catheters have broad-spectrum activity against diverse bacterial and fungal organisms. In addition, it is imperative that these agents not be the antimicrobial agents of choice for the treatment of catheter-related bloodstream infections. To minimize the emergence of resistance, a combination of antimicrobials is preferred over a single agent.
The minocycline-rifampin combination has unique characteristics that promote its consideration for incorporation onto the surface of vascular catheters. Both agents are active against methicillin-sensitive and -resistant staphylococci [32] [33] [34] [35] [36] . In addition, minocycline and rifampin are broad-spectrum agents with activity against gram-negative bacilli and candida [37] [38] [39] [40] . In combination, these agents are not antagonistic and are occasionally synergistic [41] [42] [43] . Unlike glycopeptides, penicillins, cephalosporins, aminoglycosides, quinolones, amphotericin B, or the azoles, minocycline and rifampin are not routinely used as therapeutic agents to treat bloodstream infections. In contradistinction to glycopeptide antibiotics, rifampin has not been shown to be inhibited by the exopolysaccharide fibrous glycocalyx that is generated by the slime-producing S. epidermidis [11, 44] .
The activities of minocycline-rifampin-treated catheters against gram-positive and -negative bacteria and C. albicans were significantly superior to the activities of CH-SS-treated catheters as judged by the sizes of the zones of inhibition. By using the same in vitro and in vivo rabbit model that we describe in the current study, Sherertz et a1. [20] established a quantitative relationship between the size of the zone of inhibition in vitro and the concentration of S. aureus cultured from the tip of coated catheters 7 days after inoculation of the insertion site. Coated catheters with a zone size of~15 mm were highly predictive of in vivo efficacy, as reflected by prevention of colonization of the indwelling catheter [20] . The mean zone diameter ofminocycline-rifampin-treated catheters against organisms commonly associated with vascular catheter infections (s. epidermidis, S. aureus, Corynebacterium species, and some gram-negative bacilli [e.g., S. maltophilia and A. baumanii)) was~31.0 mm (table 1) . If the conclusions of the Sherertz model can be applied to organisms other than S. aureus, the findings of this study may predict protection of minocyclinerifampin-treated catheters against colonization with such orgamsms.
The average zone of inhibition of minocycline-rifampintreated catheters against C. albicans and other gram-negative bacilli, including P. aeruginosa, was 14.8-19.6 mm, which also should be predictive of good in vivo and clinical outcome. For the CH-SS -treated catheters, the average zone of inhibition organisms tested. However, it is possible that the catheters treated with CH-SS would have sufficient antimicrobial activity to inhibit most of the organisms associated with vascular catheter-related infections. A prospective randomized clinical trial would be necessary to compare the efficacy of coating catheters with CH-SS and minocycline-rifampin. The long antimicrobial half-life (25 days) of minocyclinerifampin -treated catheters in serum at 37°C (zone~15 mm after 30 days of incubation) is predictive of long-term catheter protection against colonization with S. epidermidis. The data and the persistently large zones are consistent with the relatively high levels of minocycline (290 pg/cm) and rifampin (93 p,g/cm) bonded to the catheters. In a susceptibility study of 197 catheter-related bacteremic strains of methicillin-resistant S. epidermidis and S. aureus from the University of Texas M. D. Anderson Cancer Center, the MIC 90 of minocycline and rifampin were 2.0 and 0.06 pg/mL, respectively [43] . Although the levels of the two antibiotics are high from an antimicrobial viewpoint, from a pharmacokinetic perspective, the levels would not be expected to result in any detectable levels in the sera of patients with indwelling catheters. Assuming an indwelling catheter segment of IS em, the overall amounts of minocycline and rifampin along the subcutaneous and intravascular segments would be~4.5 and 1.5 mg, respectively. Because these quantities would be released slowly into the serum over several weeks, it should be undetectable in serum at any time point (the detectability limit in our HPLC system was 0.05 p,g/mL for both antibiotics).
The in vivo data from the rabbit experiments are consistent with the in vitro results and with reports from other animal and clinical studies. Sherertz et al. [20] demonstrated an inverse relationship between the in vitro zones of inhibition of catheters coated with antimicrobial agents and the number of S. aureus removed from a catheter indwelling an animal 7 days after inoculation of the insertion site with 10 4 cfu. In our animal experiments, we used the model described by Sherertz et al.
(except that we inoculated the insertion site with 10 5 rather than 10 4 cfu of S. aureus PI). In CH-SS-treated catheters with 12-to 14-mm zones of inhibition against S. aureus, significant colonization of indwelling catheters was noted in about onethird of cases. For catheters treated with minocycline-rifampin and with zones of inhibition of 34-39 mrn, all indwelling catheters remained sterile, and negative semiquantitative and quantitative cultures resulted in significant differences in efficacy.
We recently conducted a prospective randomized clinical study on 234 hospitalized patients in which we demonstrated the efficacy of minocycline-rifampin-coated catheters in significantly decreasing the risk of catheter colonization and in preventing catheter-related bacteremia [45] . Quantitative skininsertion-site cultures done at the time of catheter insertion and removal as well as susceptibility studies of all organisms that colonized the minocycline-rifampin-coated catheters failed to show development of resistance to minocycline or rifampin. HPLC studies on sera failed to detect either antimicrobial. The zones of inhibition of minocycline-rifampin-coated catheters removed from patients at various intervals showed that the antimicrobial protection provided by such catheters can last 2 weeks [46] . This finding is consistent with our results with minocycline-rifampin-coated catheters placed in serum, which maintained an optimal inhibitory antimicrobial activity for a similar time period.
In summary, antiinfective catheters coated with minocyclinerifampin had a broad spectrum of in vitro activity against staphylococci, other gram-positive bacteria, gram-negative bacillary organisms, and C. albicans. The efficacy ofminocycline-rifampin-treated catheters remained stable at room temperature for 12 months, and the half-life of antimicrobial activity of minocycline-rifampin-treated catheters during inoculation in serum at 37°C was 25 days. Catheters treated with these agents also effectively prevented catheter infection in a rabbit model. The in vitro and in vivo (animal) data correlate with subsequent clinical data that demonstrated the efficacy of minocyclinerifampin-coated catheters in preventing colonization and catheter-related bacteremia.
